Pre-Exposure Prophylaxis

DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.

DENVER — Data from the United States and Australia show that PrEP uptake and adherence has increased, and the incidence of HIV has declined in recent years, researchers reported.

Researchers found that implementing generic PrEP programs for young men who have sex with men at risk for HIV — a group known to have adherence and engagement issues — would reduce new infections and be cost-effective.

Clinicians should prescribe pre-exposure prophylaxis to individuals at high risk for HIV to prevent infection with the virus, the U.S. Preventive Services Task Force declared in a final recommendation statement.

In the wake of the FDA approval of the first over-the-counter birth control pill, two experts argued that the time has come to make another prevention medication available without a prescription.

Cisgender women preferred long-acting injectable PrEP over taking a daily pill for HIV prevention by a nearly 4-to-1 margin, according to study findings presented at the International AIDS Society conference.

The federal court ruling against requiring health care insurers to cover PrEP could result in more than 2,000 new and preventable HIV infections among at-risk populations within 12 months of the ruling.

SEATTLE — Two studies presented at the Conference on Retroviruses and Opportunistic infections demonstrated high adherence levels and acceptability of long-acting, injectable PrEP for HIV prevention among varying groups of people.

Demolishing social and structural barriers to access to HIV and STI prevention in transgender adolescents of color can come through gender affirmation, according to a presentation of a study at IDWeek.

Adults who initiated HIV PrEP for the first time were six times more likely to be dispensed emtricitabine/tenofovir alafenamide than emtricitabine/tenofovir disoproxil fumarate, according to study results presented at IDWeek.